Type 1 Diabetes Clinical Trial
Official title:
Very Low Carbohydrate Diet as an Adjunctive Therapy for Youth Type 1 Diabetes
Verified date | February 2024 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This prospective, open-label pilot/feasibility study of 10 youth with T1D is to evaluate glycemic and metabolic changes taking place with a very low carbohydrate diet.
Status | Completed |
Enrollment | 6 |
Est. completion date | February 20, 2022 |
Est. primary completion date | February 20, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 13 Years to 25 Years |
Eligibility | Inclusion Criteria: - BMI 19-30 m2 for individuals at least 18 years old or BMI < 95 percentile for individuals less than 18 years old - Participants 18 years of age must be able to read and provide written consent - Participants under 18 years of age must be able to read and provide written assent - Participants are managed using an insulin pump or injections - Participant has or is willing to wear a CGM for the duration of the study - Participant is willing to complete diet logging procedures stated above Exclusion Criteria: - A1c < 6.5% or > 10% - Recent history of more than 1 of diabetic ketoacidosis (DKA) in the past 6 months - Treatment with glucose-lowering drugs other than insulin - Unstable psychiatric disorders, including eating disorders (DSM-V criteria) - Weight loss medications within the last 6 months - Females who are pregnant, lactating or planning to become pregnant in the next 6 months - Another medical condition that precludes participation in the study |
Country | Name | City | State |
---|---|---|---|
United States | Yale-New Haven Hospital | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Time in Target Range of 70-180 mg/dL. | The target range is 70 mg/dL - 180 mg/dL based on sensor-derived glucose levels. The outcome is reflected as the percentage of time spent in this range during the time frame. | 2 weeks per intervention, up to 7 weeks | |
Secondary | Percentage of Time Spent > 180 mg/dL to 250 mg/dl | The percent of time spent > 180 mg/dL to 250 mg/dl based on sensor-derived glucose values. Reflected is the percentage of time spent in the range of 181-250 mg/dL. | 2 weeks per intervention, up to 7 weeks | |
Secondary | Percent Time Spent > 250 mg/dL Based on Sensor-derived Glucose Values | The percent of time spent > 250 mg/dL based on sensor-derived glucose values. Presented is the percentage of time people spent in the range. | 2 weeks per intervention, up to 7 weeks | |
Secondary | Percent of Time Spent > = 55 to < 70 mg/dL Based on Sensor-derived Glucose Values | The percent of time spent > = 55 to < 70 mg/dL based on sensor-derived glucose values. Reflected is the percentage of time within range. | 2 weeks per intervention, up to 7 weeks | |
Secondary | Percent Time Spent < 55 mg/dL Based on Sensor-derived Glucose Values | The percent of time spent < 55 mg/dL based on sensor-derived glucose values during the timeframe. Presented is the percentage of overall time spent in the specified range. | 2 weeks per intervention, up to 7 weeks | |
Secondary | Total Daily Insulin Dose | The total daily insulin dose will be defined as the average total daily insulin dose will be calculated over 2 weeks. Values represent the mean units/kg/day for the 2 week period. | 2 weeks per intervention, up to 7 weeks | |
Secondary | Average Sensor Glucose Level | The average sensor glucose level recorded by the continuous glucose monitor over the 2 week dietary period in mg/dL. | 2 weeks per intervention, up to 7 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A | |
Completed |
NCT02855307 -
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
|
Phase 2 |